SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 222 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,687,854 | -12.3% | 569,019 | -4.4% | 0.01% | -16.7% |
| Q2 2023 | $17,892,464 | -27.2% | 595,225 | -12.3% | 0.01% | -25.0% |
| Q1 2023 | $24,594,336 | -1.3% | 678,839 | -2.8% | 0.01% | -11.1% |
| Q4 2022 | $24,909,000 | -7.3% | 698,290 | -12.0% | 0.01% | -10.0% |
| Q3 2022 | $26,861,000 | +12.6% | 793,557 | -3.8% | 0.01% | +25.0% |
| Q2 2022 | $23,860,000 | -12.9% | 825,060 | -2.6% | 0.01% | 0.0% |
| Q1 2022 | $27,384,000 | +13.8% | 847,315 | +2.7% | 0.01% | +14.3% |
| Q4 2021 | $24,066,000 | +7.5% | 825,328 | -1.7% | 0.01% | 0.0% |
| Q3 2021 | $22,389,000 | -9.5% | 839,518 | +4.5% | 0.01% | -12.5% |
| Q2 2021 | $24,732,000 | +23.5% | 803,241 | +5.0% | 0.01% | +14.3% |
| Q1 2021 | $20,027,000 | +5.4% | 764,977 | +1.3% | 0.01% | 0.0% |
| Q4 2020 | $18,998,000 | +32.0% | 755,054 | +9.3% | 0.01% | +16.7% |
| Q3 2020 | $14,397,000 | -5.0% | 690,738 | +8.2% | 0.01% | 0.0% |
| Q2 2020 | $15,158,000 | +7.6% | 638,245 | -18.5% | 0.01% | -14.3% |
| Q1 2020 | $14,091,000 | -21.8% | 783,292 | +3.1% | 0.01% | 0.0% |
| Q4 2019 | $18,027,000 | +4.0% | 760,009 | +20.5% | 0.01% | -12.5% |
| Q3 2019 | $17,326,000 | -24.3% | 630,575 | -8.9% | 0.01% | -20.0% |
| Q2 2019 | $22,896,000 | +47.3% | 691,958 | +56.0% | 0.01% | +42.9% |
| Q1 2019 | $15,539,000 | -2.5% | 443,433 | -7.6% | 0.01% | -12.5% |
| Q4 2018 | $15,941,000 | -30.9% | 479,837 | +4.7% | 0.01% | 0.0% |
| Q3 2018 | $23,078,000 | -29.8% | 458,374 | -16.5% | 0.01% | -46.7% |
| Q2 2018 | $32,872,000 | +21.8% | 549,265 | -6.8% | 0.02% | +25.0% |
| Q1 2018 | $26,994,000 | +12.8% | 589,435 | -1.9% | 0.01% | +9.1% |
| Q4 2017 | $23,933,000 | -12.2% | 600,554 | -11.9% | 0.01% | -15.4% |
| Q3 2017 | $27,271,000 | +9.2% | 681,792 | +17.7% | 0.01% | 0.0% |
| Q2 2017 | $24,974,000 | +29.9% | 579,451 | -5.7% | 0.01% | +30.0% |
| Q1 2017 | $19,230,000 | -15.2% | 614,419 | -31.6% | 0.01% | -16.7% |
| Q4 2016 | $22,685,000 | +3.2% | 898,381 | +1.0% | 0.01% | 0.0% |
| Q3 2016 | $21,989,000 | +18.3% | 889,065 | -2.6% | 0.01% | +9.1% |
| Q2 2016 | $18,592,000 | +56.7% | 912,740 | +17.3% | 0.01% | +57.1% |
| Q1 2016 | $11,868,000 | +18.8% | 778,196 | +4.7% | 0.01% | +16.7% |
| Q4 2015 | $9,992,000 | -12.9% | 743,441 | -9.1% | 0.01% | -14.3% |
| Q3 2015 | $11,469,000 | -46.5% | 817,482 | -35.3% | 0.01% | -41.7% |
| Q2 2015 | $21,444,000 | +24.2% | 1,263,024 | -11.6% | 0.01% | +20.0% |
| Q1 2015 | $17,264,000 | +41.8% | 1,427,997 | -2.6% | 0.01% | +42.9% |
| Q4 2014 | $12,172,000 | -4.7% | 1,466,709 | -0.2% | 0.01% | -12.5% |
| Q3 2014 | $12,775,000 | -32.7% | 1,470,097 | -15.1% | 0.01% | -27.3% |
| Q2 2014 | $18,972,000 | +14.3% | 1,732,581 | -6.7% | 0.01% | +10.0% |
| Q1 2014 | $16,604,000 | +11.2% | 1,857,351 | -6.2% | 0.01% | +11.1% |
| Q4 2013 | $14,929,000 | +155.3% | 1,980,077 | +148.3% | 0.01% | +125.0% |
| Q3 2013 | $5,847,000 | +1.9% | 797,352 | -10.6% | 0.00% | 0.0% |
| Q2 2013 | $5,737,000 | – | 892,122 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthInvest Partners AB | 335,000 | $8,934,000 | 13.38% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,016,665 | $27,114,000 | 2.46% |
| Bruce & Co., Inc. | 402,105 | $10,724,000 | 2.28% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $7,934,000 | 1.91% |
| ARMISTICE CAPITAL, LLC | 3,900,000 | $104,013,000 | 1.76% |
| Bridge City Capital, LLC | 108,884 | $2,904,000 | 1.32% |
| S&T BANK/PA | 316,098 | $8,430,000 | 1.31% |
| Kent Lake Capital LLC | 100,000 | $2,667,000 | 1.15% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 331,140 | $8,832,000 | 1.02% |
| Prairiewood Capital, LLC | 45,297 | $1,208,000 | 0.99% |